This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Mtb72F/AS02A

GlaxoSmithKline plc

Drug Names(s): Mtb72F/AS02A

Description: Mtb72F/AS02A is a TB vaccine that contains a polyprotein derived from two known M. tuberculosis antigens adjuvanted with AS02A.

Deal Structure: GSK and Aeras
In October 2005, GlaxoSmithKline and Aeras announced a new public-private partnership to develop GSK Biologicals' tuberculosis candidate vaccine Mtb72F/AS02A.

Over the coming months, GSK and Aeras plan to move forward with additional safety and immunogenicity trials in Europe involving adults previously infected with TB or vaccinated with Bacillus Calmette-Gurin (BCG). The plan is then to begin studies in Africa and other locations to test the safety and efficacy of the vaccine candidate in populations highly affected by TB. GSK, who will provide its candidate vaccine, will be responsible for conducting these clinical trials.

Partners: Aeras


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug